|
US8481043B2
(en)
*
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
|
US20100266638A1
(en)
|
2004-02-26 |
2010-10-21 |
Allergan, Inc. |
Headache treatment method
|
|
US9078892B2
(en)
*
|
2004-02-26 |
2015-07-14 |
Allergan, Inc. |
Methods for treating pain and for treating a medication overuse disorder
|
|
US20050191321A1
(en)
*
|
2004-02-26 |
2005-09-01 |
Allergan, Inc. |
Methods for treating headache
|
|
CA2620202C
(en)
*
|
2005-08-26 |
2016-10-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Therapy procedure for drug delivery for trigeminal pain
|
|
KR101441843B1
(ko)
|
2005-10-18 |
2014-09-17 |
내셔날 쥬이쉬 헬스 |
조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
|
|
MY153249A
(en)
|
2005-11-14 |
2015-01-29 |
Rinat Neuroscience Corp |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
|
US20080261893A1
(en)
*
|
2006-02-24 |
2008-10-23 |
Denise Barbut |
Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
|
|
WO2007120485A2
(en)
*
|
2006-03-30 |
2007-10-25 |
Cinergen, Llc |
Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
|
|
GB2438834A
(en)
|
2006-06-08 |
2007-12-12 |
Optinose As |
Intranasal protein administration
|
|
US7645767B2
(en)
*
|
2006-08-31 |
2010-01-12 |
Trinity Laboratories, Inc. |
Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
|
|
EP2131651B1
(en)
*
|
2007-03-12 |
2013-05-22 |
Sarentis Therapeutics, Inc. |
Topical corneal analgesia using neurotensin receptor agonists
|
|
EP2134852A4
(en)
*
|
2007-03-13 |
2010-04-28 |
Nat Jewish Health |
PROCESS FOR THE PRODUCTION OF ANTIBODIES
|
|
US9707274B2
(en)
|
2007-06-08 |
2017-07-18 |
Healthpartners Research & Education |
Methods for preventing and treating post-traumatic stress disorder (PTSD)
|
|
EP2152240A4
(en)
*
|
2007-06-08 |
2012-05-09 |
Healthpartners Res Foundation |
PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM
|
|
WO2009012376A1
(en)
*
|
2007-07-17 |
2009-01-22 |
The Ohio State University Research Foundation |
Compositions and methods for skin care
|
|
EP2197469A2
(en)
*
|
2007-09-11 |
2010-06-23 |
Mondobiotech Laboratories AG |
Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection
|
|
WO2009043440A2
(en)
*
|
2007-09-11 |
2009-04-09 |
Mondobiotech Laboratories Ag |
Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent
|
|
RU2010114025A
(ru)
*
|
2007-09-11 |
2011-10-20 |
Мондобайотек Лабораториз Аг (Li) |
ПРИМЕНЕНИЕ ПЕПТИДА Gly-Arg-Gly-Asp-Asn-Pro В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
|
|
WO2009046848A1
(en)
*
|
2007-09-11 |
2009-04-16 |
Mondobiotech Laboratories Ag |
Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent
|
|
WO2009033489A2
(en)
*
|
2007-09-11 |
2009-03-19 |
Glostrup Hospital |
Selective pacl inhibitors for use in the treatment of migraine and headaches
|
|
CA2716424C
(en)
|
2008-03-04 |
2015-04-28 |
Pfizer Limited |
Methods of treating chronic pain
|
|
WO2009145956A2
(en)
*
|
2008-03-06 |
2009-12-03 |
The Trustees Of Columbia University In The City Of New York |
Uses of calpain inhibitors to inhibit inflammation
|
|
US20090246273A1
(en)
*
|
2008-03-27 |
2009-10-01 |
Al-Ghananeem Abeer M |
Ketorolac Sublingual Spray for the Treatment of Pain
|
|
EP2285832B1
(en)
|
2008-05-16 |
2020-08-26 |
Taiga Biotechnologies, Inc. |
Antibodies and processes for preparing the same
|
|
FR2932483A1
(fr)
*
|
2008-06-13 |
2009-12-18 |
Cytomics Systems |
Composes utiles pour le traitement des cancers.
|
|
ES2525411T3
(es)
*
|
2008-07-21 |
2014-12-22 |
Taiga Biotechnologies, Inc. |
Células anucleadas diferenciadas y método para preparar las mismas
|
|
EP2318435B1
(en)
|
2008-08-28 |
2015-12-23 |
Taiga Biotechnologies, Inc. |
Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
|
|
WO2010029555A1
(en)
*
|
2008-09-12 |
2010-03-18 |
Slender Medical, Ltd. |
Virtual ultrasonic scissors
|
|
US20110318345A1
(en)
*
|
2008-09-15 |
2011-12-29 |
Optinose As |
Nasal delivery
|
|
US8802681B2
(en)
*
|
2008-10-17 |
2014-08-12 |
Signature Therapeutics, Inc. |
Pharmaceutical compositions with attenuated release of phenolic opioids
|
|
US8575309B2
(en)
|
2008-12-08 |
2013-11-05 |
Biousian Biosystems, Inc. |
Delta-opioid receptor selective analgesics
|
|
EP2393488B1
(en)
*
|
2009-02-06 |
2019-06-19 |
University Of Southern California |
Therapeutic compositions comprising monoterpenes
|
|
JP2012526840A
(ja)
*
|
2009-05-13 |
2012-11-01 |
プロテイン デリヴァリー ソリューションズ エルエルシー |
膜貫通送達のための製剤系
|
|
US9107876B2
(en)
|
2009-07-02 |
2015-08-18 |
Yamaguchi University |
Surface anesthetic agent
|
|
SG10201406930UA
(en)
*
|
2009-07-27 |
2014-11-27 |
Nocicepta Llc |
Methods For Treatment Of Pain
|
|
FR2948809B1
(fr)
*
|
2009-07-31 |
2012-08-17 |
St Microelectronics Rousset |
Amplificateur de lecture faible puissance auto-minute
|
|
KR101519192B1
(ko)
|
2009-08-28 |
2015-05-11 |
리나트 뉴로사이언스 코프. |
칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
|
|
BR112012005124B1
(pt)
|
2009-09-08 |
2021-11-09 |
Signature Therapeutics, Inc. |
Pro-fármaco de opioide modificado por cetona, seu método de preparação, sua composição farmacêutica, sua unidade de dose, métodos e usos
|
|
WO2011075688A1
(en)
*
|
2009-12-18 |
2011-06-23 |
Exodos Life Sciences Limited Partnership |
Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
|
|
US8622993B2
(en)
*
|
2009-12-18 |
2014-01-07 |
Healthpartners Research Foundation |
Device and method for delivering therapeutic substances to the maxillary sinus of a patient
|
|
US20110184322A1
(en)
*
|
2010-01-22 |
2011-07-28 |
Slender Medical Ltd. |
Method and device for treatment of keloids and hypertrophic scars using focused ultrasound
|
|
EP2542082B8
(en)
|
2010-03-03 |
2020-06-17 |
Neonc Technologies Inc. |
PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-perillyl alcohol
|
|
US9238020B2
(en)
|
2010-04-21 |
2016-01-19 |
Signature Therapeutics, Inc. |
Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
|
|
US20110262355A1
(en)
|
2010-04-21 |
2011-10-27 |
Jenkins Thomas E |
Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
|
|
US20130059914A1
(en)
|
2010-04-21 |
2013-03-07 |
Signature Therapeutics, Inc. |
Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
|
|
US20130089504A1
(en)
*
|
2010-04-21 |
2013-04-11 |
Signature Therapeutics, Inc. |
Compositions Comprising Enzyme-Cleavable Hydromorphone Prodrug
|
|
US9242122B2
(en)
|
2010-05-14 |
2016-01-26 |
Liat Tsoref |
Reflectance-facilitated ultrasound treatment and monitoring
|
|
US8956346B2
(en)
|
2010-05-14 |
2015-02-17 |
Rainbow Medical, Ltd. |
Reflectance-facilitated ultrasound treatment and monitoring
|
|
US8617150B2
(en)
|
2010-05-14 |
2013-12-31 |
Liat Tsoref |
Reflectance-facilitated ultrasound treatment
|
|
EP2571511B1
(en)
|
2010-05-18 |
2014-10-08 |
Université de Genève |
New uses of oxytocin-like molecules and related methods
|
|
AR082189A1
(es)
*
|
2010-07-06 |
2012-11-21 |
Gruenenthal Gmbh |
Formas de dosificacion gastrorretentivas, procedimiento
|
|
US20160038600A1
(en)
|
2012-08-03 |
2016-02-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising poh derivatives
|
|
DK3685835T3
(da)
|
2010-08-27 |
2025-07-21 |
Univ Southern California |
Farmaceutiske sammensætninger, der omfatter derivater af perillylalkohol
|
|
GB201015371D0
(en)
*
|
2010-09-14 |
2010-10-27 |
Optinose As |
Nasal delivery
|
|
US8647661B1
(en)
*
|
2010-11-05 |
2014-02-11 |
Florida A&M University |
Surface modified multilayered nanostructures for dermal delivery
|
|
ES3056006T3
(en)
|
2010-12-17 |
2026-02-17 |
Univ Southern California |
Methods and devices for using isoperillyl alcohol
|
|
ES2584634T3
(es)
|
2011-01-11 |
2016-09-28 |
Signature Therapeutics, Inc. |
Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
|
|
WO2012096886A1
(en)
|
2011-01-11 |
2012-07-19 |
Signature Therapeutics, Inc. |
Compositions comprising enzyme-cleavable oxycodone prodrug
|
|
US20120183580A1
(en)
*
|
2011-01-13 |
2012-07-19 |
Theralpha |
Analgesic Composition for Transbuccal Administration
|
|
US12279989B2
(en)
|
2011-02-04 |
2025-04-22 |
Seed Health, Inc. |
Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
|
|
US11998479B2
(en)
|
2011-02-04 |
2024-06-04 |
Seed Health, Inc. |
Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
|
|
US12257272B2
(en)
|
2015-12-24 |
2025-03-25 |
Seed Health, Inc. |
Method and system for reducing the likelihood of developing depression in an individual
|
|
US11951140B2
(en)
|
2011-02-04 |
2024-04-09 |
Seed Health, Inc. |
Modulation of an individual's gut microbiome to address osteoporosis and bone disease
|
|
US12533312B2
(en)
|
2011-02-04 |
2026-01-27 |
Seed Health, Inc. |
Method and system for preventing sore throat in humans
|
|
US11523934B2
(en)
|
2011-02-04 |
2022-12-13 |
Seed Health, Inc. |
Method and system to facilitate the growth of desired bacteria in a human's mouth
|
|
US11844720B2
(en)
|
2011-02-04 |
2023-12-19 |
Seed Health, Inc. |
Method and system to reduce the likelihood of dental caries and halitosis
|
|
US10687975B2
(en)
*
|
2011-02-04 |
2020-06-23 |
Joseph E. Kovarik |
Method and system to facilitate the growth of desired bacteria in a human's mouth
|
|
US11951139B2
(en)
|
2015-11-30 |
2024-04-09 |
Seed Health, Inc. |
Method and system for reducing the likelihood of osteoporosis
|
|
AU2012225337B2
(en)
|
2011-03-09 |
2016-04-28 |
Signature Therapeutics, Inc. |
Active agent prodrugs with heterocyclic linkers
|
|
WO2012122420A2
(en)
|
2011-03-09 |
2012-09-13 |
Pharmacofore, Inc. |
Opioid prodrugs with heterocyclic linkers
|
|
WO2012123819A1
(en)
|
2011-03-15 |
2012-09-20 |
Optinose As Et Al |
Nasal delivery
|
|
RS58064B1
(sr)
|
2011-04-05 |
2019-02-28 |
Gruenenthal Gmbh |
Tapentadol za sprečavanje hronifikacije bola
|
|
US20120309840A1
(en)
*
|
2011-04-05 |
2012-12-06 |
Gruenenthal Gmbh |
Treatment of Pain Associated with Trigeminal Neuralgia
|
|
LT3272343T
(lt)
|
2011-04-29 |
2020-05-11 |
Grünenthal GmbH |
Tapentadolis, skirtas depresijos ir nerimo prevencijai ir gydymui
|
|
US8609088B2
(en)
|
2011-05-10 |
2013-12-17 |
Regents Of The University Of Minnesota |
Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
|
|
WO2012174481A1
(en)
|
2011-06-15 |
2012-12-20 |
Nerve Access, Inc. |
Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
|
|
US9402877B2
(en)
|
2011-11-04 |
2016-08-02 |
Xion Pharmaceuticals Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|
|
US9962391B2
(en)
|
2011-12-27 |
2018-05-08 |
Cmpd Licensing, Llc |
Composition and method for compounded therapy
|
|
US11213501B2
(en)
|
2011-12-27 |
2022-01-04 |
Cmpd Licensing, Llc |
Composition and method for compounded therapy
|
|
US11213500B2
(en)
|
2011-12-27 |
2022-01-04 |
Cmpd Licensing, Llc |
Composition and method for compounded therapy
|
|
US9468599B2
(en)
|
2011-12-27 |
2016-10-18 |
Cmpd Licensing, Llc |
Composition and method for compounded therapy
|
|
US10813897B2
(en)
|
2011-12-27 |
2020-10-27 |
Cmpd Licensing, Llc |
Composition and method for compounded therapy
|
|
US20130178419A1
(en)
*
|
2012-01-05 |
2013-07-11 |
Beech Tree Labs, Inc. |
Method of treating pain by administration of nerve growth factor
|
|
US9707414B2
(en)
|
2012-02-14 |
2017-07-18 |
Rainbow Medical Ltd. |
Reflectance-facilitated ultrasound treatment and monitoring
|
|
WO2013122778A1
(en)
|
2012-02-15 |
2013-08-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of treating and preventing diseases and disorders of the central nervous system
|
|
JP6285930B2
(ja)
|
2012-07-20 |
2018-02-28 |
タイガ バイオテクノロジーズ，インク． |
造血コンパートメントの再構築及び自家再構築の増進
|
|
ES2442242B1
(es)
*
|
2012-08-09 |
2014-11-25 |
Biotechnology Institute, I Mas D, S.L. |
Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
|
|
US9770593B2
(en)
|
2012-11-05 |
2017-09-26 |
Pythagoras Medical Ltd. |
Patient selection using a transluminally-applied electric current
|
|
WO2014068577A2
(en)
|
2012-11-05 |
2014-05-08 |
Rainbow Medical Ltd. |
Controlled tissue ablation
|
|
CN104813167B
(zh)
*
|
2012-11-28 |
2019-04-09 |
尼克塔治疗公司 |
用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
|
|
US9050330B2
(en)
*
|
2012-12-06 |
2015-06-09 |
Jose C. Ramon-de-Jesus |
Method, composition and kit for treating frequent headaches
|
|
US10639439B2
(en)
|
2013-01-30 |
2020-05-05 |
Midwest Pharmaceuticals, Llc |
Smokeless THC and administration method thereof
|
|
WO2014130581A1
(en)
*
|
2013-02-20 |
2014-08-28 |
Questcor Pharmaceuticals, Inc. |
Acth for treatment of migraine headache
|
|
US10272115B2
(en)
|
2013-03-11 |
2019-04-30 |
Taiga Biotechnologies, Inc. |
Production and use of red blood cells
|
|
US9365825B2
(en)
|
2013-03-11 |
2016-06-14 |
Taiga Biotechnologies, Inc. |
Expansion of adult stem cells in vitro
|
|
CA2906737C
(en)
|
2013-03-15 |
2023-08-15 |
Amgen Inc. |
Human pac1 antibodies
|
|
CN105377039A
(zh)
|
2013-05-15 |
2016-03-02 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
|
US20150086616A1
(en)
*
|
2013-09-20 |
2015-03-26 |
Steven Lehrer |
Method for the prevention and treatment of alzheimer's disease
|
|
US12329783B2
(en)
|
2013-12-20 |
2025-06-17 |
Seed Health, Inc. |
Method and system to improve the health of a person's skin microbiome
|
|
US12005085B2
(en)
|
2013-12-20 |
2024-06-11 |
Seed Health, Inc. |
Probiotic method and composition for maintaining a healthy vaginal microbiome
|
|
US11980643B2
(en)
|
2013-12-20 |
2024-05-14 |
Seed Health, Inc. |
Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
|
|
US11826388B2
(en)
|
2013-12-20 |
2023-11-28 |
Seed Health, Inc. |
Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
|
|
US11833177B2
(en)
|
2013-12-20 |
2023-12-05 |
Seed Health, Inc. |
Probiotic to enhance an individual's skin microbiome
|
|
US12246043B2
(en)
|
2013-12-20 |
2025-03-11 |
Seed Health, Inc. |
Topical application to treat acne vulgaris
|
|
US11998574B2
(en)
|
2013-12-20 |
2024-06-04 |
Seed Health, Inc. |
Method and system for modulating an individual's skin microbiome
|
|
US11839632B2
(en)
|
2013-12-20 |
2023-12-12 |
Seed Health, Inc. |
Topical application of CRISPR-modified bacteria to treat acne vulgaris
|
|
US11969445B2
(en)
|
2013-12-20 |
2024-04-30 |
Seed Health, Inc. |
Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
|
|
PE20161439A1
(es)
|
2014-03-21 |
2017-01-26 |
Teva Pharmaceuticals Int Gmbh |
Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
|
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
|
WO2015170281A1
(en)
|
2014-05-07 |
2015-11-12 |
Rainbow Medical Ltd |
Controlled tissue ablation techniques
|
|
WO2015195708A1
(en)
*
|
2014-06-16 |
2015-12-23 |
Loewi LLC |
Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
|
|
WO2016044224A1
(en)
|
2014-09-15 |
2016-03-24 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
|
RU2701199C2
(ru)
*
|
2014-10-01 |
2019-09-25 |
Окситон Байосайенс Б.В. |
Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество
|
|
PL3200764T3
(pl)
*
|
2014-10-01 |
2020-12-28 |
Oxytone Bioscience B.V. |
Rozpadająca się w jamie ustnej stała farmaceutyczna jednostka dawkowania zawierająca substancję kontrolującą poród
|
|
SG10202011669PA
(en)
|
2014-10-20 |
2020-12-30 |
Oyster Point Pharma Inc |
Methods of treating ocular conditions
|
|
AU2015335907A1
(en)
|
2014-10-21 |
2017-04-13 |
Psomagen, Inc. |
Method and system for microbiome-derived diagnostics and therapeutics
|
|
US10388407B2
(en)
|
2014-10-21 |
2019-08-20 |
uBiome, Inc. |
Method and system for characterizing a headache-related condition
|
|
MY188242A
(en)
|
2014-11-19 |
2021-11-24 |
Optinose As |
Intranasal administration
|
|
EP3226972A4
(en)
|
2014-12-01 |
2018-08-08 |
Achelios Therapeutics, Inc. |
Methods and compositions for treating migraine and conditions associated with pain
|
|
SG11201705591PA
(en)
*
|
2015-01-07 |
2017-08-30 |
Trigemina Inc |
Magnesium-containing oxytocin formulations and methods of use
|
|
US9937223B2
(en)
|
2015-01-30 |
2018-04-10 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
|
US9687526B2
(en)
|
2015-01-30 |
2017-06-27 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
|
US9744239B2
(en)
|
2015-01-30 |
2017-08-29 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
|
US9744209B2
(en)
|
2015-01-30 |
2017-08-29 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
|
US9925233B2
(en)
|
2015-01-30 |
2018-03-27 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
|
US9750785B2
(en)
|
2015-01-30 |
2017-09-05 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
|
JP6674957B2
(ja)
|
2015-02-12 |
2020-04-01 |
ネオンク テクノロジーズ インク． |
ペリリルアルコール誘導体を含む医薬組成物
|
|
JP6734258B2
(ja)
*
|
2015-03-04 |
2020-08-05 |
栄研化学株式会社 |
オキシトシンの高感度測定法
|
|
CA2982861A1
(en)
|
2015-04-16 |
2016-10-20 |
Alder Biopharmaceuticals, Inc. |
Anti-pacap antibodies and uses thereof
|
|
US10383685B2
(en)
|
2015-05-07 |
2019-08-20 |
Pythagoras Medical Ltd. |
Techniques for use with nerve tissue
|
|
US11207461B2
(en)
|
2015-07-30 |
2021-12-28 |
Anoop U. R |
Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
|
|
US11213480B1
(en)
|
2015-08-06 |
2022-01-04 |
Hikma Pharmaceuticals International Limited |
Phenylephrine hydrochloride ready-to-use solution
|
|
US10335406B2
(en)
|
2015-10-01 |
2019-07-02 |
Elysium Therapeutics, Inc. |
Opioid compositions resistant to overdose and abuse
|
|
JP2018534269A
(ja)
|
2015-10-01 |
2018-11-22 |
エリージウム セラピューティクス， インコーポレイテッド |
過剰摂取および乱用に抵抗性のポリサブユニットオピオイドプロドラッグ
|
|
US10822408B2
(en)
|
2015-12-15 |
2020-11-03 |
Amgen Inc. |
PACAP antibodies and uses thereof
|
|
HUE070412T2
(hu)
*
|
2016-04-12 |
2025-06-28 |
Tonix Pharma Ltd |
Magnézium tartalmú oxitocin készítmények és alkamazási eljárásaik
|
|
EP3426288A4
(en)
|
2016-04-15 |
2019-10-30 |
Alder Biopharmaceuticals, Inc. |
ANTI-PACAP ANTIBODIES AND USES THEREOF
|
|
IL305449B2
(en)
|
2016-04-15 |
2026-01-01 |
Univ Pennsylvania |
Gene therapy for the treatment of mucocutaneous type ii diabetes
|
|
US11678932B2
(en)
|
2016-05-18 |
2023-06-20 |
Symap Medical (Suzhou) Limited |
Electrode catheter with incremental advancement
|
|
WO2018055574A1
(en)
|
2016-09-23 |
2018-03-29 |
Teva Pharmaceuticals International Gmbh |
Treating refractory migraine
|
|
WO2018094376A1
(en)
*
|
2016-11-21 |
2018-05-24 |
uBiome, Inc. |
Method and system for characterizing a headache-related condition
|
|
EP3547836B1
(en)
|
2016-11-30 |
2024-08-21 |
University of Southern California |
A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
|
|
KR20190092472A
(ko)
|
2016-12-02 |
2019-08-07 |
타이가 바이오테크놀로지스, 인코포레이티드 |
나노입자 제제
|
|
US10932711B2
(en)
|
2017-02-27 |
2021-03-02 |
Payman Sadeghi |
Method and system for neurohydrodissection
|
|
US10456419B2
(en)
|
2017-02-27 |
2019-10-29 |
Payman Sadeghi |
Method for treating migraine headaches
|
|
EP3595663A4
(en)
|
2017-03-17 |
2021-01-13 |
Elysium Therapeutics, Inc. |
MULTIPLE SUBUNITY OPIOID PRODRUGS WITH RESISTANCE TO OVERDOSE AND ABUSE
|
|
US10149898B2
(en)
|
2017-08-03 |
2018-12-11 |
Taiga Biotechnologies, Inc. |
Methods and compositions for the treatment of melanoma
|
|
TWI835747B
(zh)
|
2017-09-22 |
2024-03-21 |
賓州大學委員會 |
用於治療黏多醣病 ii 型之基因治療
|
|
UY38050A
(es)
*
|
2018-01-12 |
2019-07-31 |
Amgen Inc |
Anticuerpos pac1 y sus usos referencia cruzada a solicitudes relacionadas
|
|
CN111936125B
(zh)
|
2018-02-08 |
2025-03-04 |
南加州大学 |
穿透血脑屏障的方法
|
|
US20210346385A1
(en)
*
|
2018-09-21 |
2021-11-11 |
MSB Holdings, Inc |
Taste-masked dosage forms
|
|
US11135379B2
(en)
|
2019-02-15 |
2021-10-05 |
Bn Intellectual Properties, Inc. |
Method of delivering pharmaceutical products
|
|
CA3132082A1
(en)
|
2019-03-14 |
2020-09-17 |
Om Pharma Sa |
Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders
|
|
WO2020210231A1
(en)
|
2019-04-08 |
2020-10-15 |
Taiga Biotechnologies, Inc. |
Compositions and methods for the cry opreservation of immune cells
|
|
EP3969041A4
(en)
|
2019-05-14 |
2023-05-10 |
Taiga Biotechnologies, Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
|
|
WO2021016190A1
(en)
*
|
2019-07-19 |
2021-01-28 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Compositions and methods for modulating drug-use disorders
|
|
US11364225B2
(en)
*
|
2019-08-21 |
2022-06-21 |
Bn Intellectual Properties, Inc. |
Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
|
|
CA3152988A1
(en)
*
|
2019-08-29 |
2021-03-04 |
New York University |
Oxytocin compositions for treatment of tinnitus
|
|
WO2021072055A1
(en)
*
|
2019-10-11 |
2021-04-15 |
Board Of Regents, The University Of Texas System |
Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
|
|
WO2021151100A1
(en)
|
2020-01-24 |
2021-07-29 |
Aim Immunotech Inc. |
Methods, compositions, and vaccines for treating a virus infection
|
|
WO2023048748A1
(en)
*
|
2020-08-10 |
2023-03-30 |
Ziropa, Inc. |
Compositions and methods for topical delivery
|
|
US12599578B2
(en)
|
2021-03-09 |
2026-04-14 |
Ensysce Biosciences Inc. |
Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
|
|
MX2024003466A
(es)
|
2021-09-29 |
2024-06-04 |
Ensysce Biosciences Inc |
Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.
|
|
WO2023146579A1
(en)
*
|
2022-01-27 |
2023-08-03 |
Belnap Pharmaceuticals, Llc |
Methods of treatment using oxytocin
|
|
AU2023375349A1
(en)
*
|
2022-11-07 |
2025-05-22 |
AEON Biopharma, Inc. |
Compositions for use in treating headache disorders
|
|
WO2025064708A1
(en)
*
|
2023-09-22 |
2025-03-27 |
The George Washington University |
Compositions comprising oxytocin and methods of treating opioid overdose
|
|
WO2025199179A2
(en)
|
2024-03-18 |
2025-09-25 |
Tonix Pharmaceuticals Holding Corp. |
Oxytocin peptide analogs
|